NASDAQ:KOD Kodiak Sciences Q2 2026 Earnings Report $31.52 -2.28 (-6.75%) Closing price 09/23/2026 04:00 PM EasternExtended Trading$31.32 -0.20 (-0.62%) As of 08:28 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Kodiak Sciences EPS ResultsActual EPS-$1.05Consensus EPS -$0.96Beat/MissMissed by -$0.09One Year Ago EPSN/AKodiak Sciences Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AKodiak Sciences Announcement DetailsQuarterQ2 2026Date8/12/2026TimeAfter Market ClosesConference Call DateThursday, August 13, 2026Conference Call Time4:00PM ETUpcoming EarningsKodiak Sciences' Q3 2026 earnings is estimated for Thursday, November 12, 2026, based on past reporting schedules, with a conference call scheduled at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Kodiak Sciences Earnings HeadlinesThe Zacks Analyst Blog Highlights Kodiak Sciences, Celldex Therapeutics, Rapport Therapeutics and VaxcyteSeptember 23 at 11:30 PM | finance.yahoo.comAnalysts Set Kodiak Sciences Inc. (NASDAQ:KOD) Target Price at $48.14September 23 at 3:59 AM | americanbankingnews.comWhile SpaceX Gets the Spotlight, FJET Is Building What Comes Next!Starfighters Space (NYSE: FJET) operates the world's only commercial fleet of flight-ready Mach 2+ F-104 Starfighter aircraft, giving it a rare platform for high-speed flight testing, captive-carry missions and aerospace research. Its Wind Tunnel in the Sky concept exposes hardware to real high-speed atmospheric conditions, while new collaborations with Vaya Defense & Space and The Bionetics Corporation expand its reach into propulsion, hypersonic test articles and payload processing. FJET is also developing STARLAUNCH, an air-launched system targeting suborbital missions, positioning the company across testing, defense and launch.September 24 at 1:00 AM | Trading Wire (Ad)HC Wainwright Reiterates "Buy" Rating for Kodiak Sciences (NASDAQ:KOD)September 19, 2026 | americanbankingnews.comKodiak Sciences: Daybreak Needs To Deliver More Than A Passing GradeSeptember 16, 2026 | seekingalpha.comKodiak Sciences (KOD) Races Toward Three Make-Or-Break Trial VerdictsSeptember 3, 2026 | insidermonkey.comSee More Kodiak Sciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Kodiak Sciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Kodiak Sciences and other key companies, straight to your email. Email Address About Kodiak SciencesKodiak Sciences (NASDAQ:KOD) (NASDAQ: KOD) is a biopharmaceutical company focused on developing therapies for retinal diseases and other conditions affecting the eye. The company’s research is centered on antibody biopolymer conjugates, a technology designed to extend the duration of action of biologic medicines in ocular tissues and potentially reduce the frequency of administration. Its lead development program has been tarcocimab tedromer, also known as KSI-301, an anti-vascular endothelial growth factor (VEGF) therapy investigated for retinal vascular diseases, including diabetic macular edema, diabetic retinopathy and neovascular age-related macular degeneration. Kodiak has also pursued KSI-501, a bispecific antibody biopolymer conjugate designed to target both VEGF and interleukin-6 pathways in retinal disease. Founded in 2009 and based in Palo Alto, California, Kodiak Sciences has focused primarily on research and clinical development rather than commercialized products. The company was founded and led by Victor H. Perlroth, who has served as its chief executive officer and a member of its board. Its clinical development activities have primarily addressed global ophthalmology markets through clinical trials and collaborations.View Kodiak Sciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Energy Transfer Taps the AI Power BoomFull Throttle: Kratos and GE Fire Up a Next-Gen Defense EngineSandisk Joins the S&P 100—Is the Index Flow, or the AI Story, Driving the Stock?Thor Industries Is Boring—And That May Be Its Biggest AdvantageAutoZone Shifts Gears, On Track to Reverse Course and Price RecoveryMeta’s Muse Highlights Arm’s Growing Role in AI InfrastructureOld Dogs, New Tech: 3 Legacy Stocks Powering the AI Boom Upcoming Earnings Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
